###### Article summary

Strengths and limitations of this study
=======================================

-   This is the first population-based case--control study using predetermined criteria for asthma status and community-acquired *Escherichia coli* bloodstream infection. Also, our study setting has the epidemiologic merits of self-contained healthcare environment with comprehensive medical record system for research.

-   The study has inherent limitations as a retrospective study. The study participants were predominantly white and were a relatively older population.

Introduction {#s1}
============

Asthma is the most common chronic illness in childhood and is a major cause of morbidity in adults, affecting 4--17% of children and 7.7% of adults in the USA.[@R1; @R2; @R3] About 300 million people globally are estimated to be affected by asthma.[@R4]

Previous studies showed increased risks of microbial infections among individuals with asthma[@R5; @R6; @R7; @R8; @R9; @R10] and the population attributable risk for asthma of serious pneumococcal disease was 11--17%.[@R6] [@R10] Impaired innate and adaptive immune functions among asthmatics have been suggested for potential underlying mechanisms.[@R11; @R12; @R13; @R14; @R15; @R16; @R17; @R18] These study results are based on microbial infections of the airways. However, little is known about whether asthma status is associated with the risk of non-airway-related bacterial infections such as community-acquired *Escherichia coli* bloodstream infection (BSI).

Addressing this question should provide an important insight into the nature of the impact of asthma status on susceptibility to microbial infection. Specifically, it will improve our understanding on whether the impact of asthma status on susceptibility to infection goes beyond airways. In investigating this question, community-acquired *E coli* BSI is suitable because it is not an airway-related infection but genitourinary tract/gastrointestinal origin, *E coli* is a Gram-negative bacterium with Toll-like receptor (TLR)-4-mediated signal transduction for innate immunity and *E coli* is the most common cause of community-acquired BSI.[@R19] Up to 30% of individuals who developed community-acquired *E coli* BSI did not have known risk factors,[@R20] suggesting that unrecognised risk factors exist that are associated with the development of community-acquired *E coli* BSI.

Investigating the relationship between asthma and non-airway-related serious bacterial infections will advance our understanding on the extent to which asthma impacts susceptibility to microbial infections and whether asthma could be an unrecognised risk factor for non-airway-related bacterial infections.

We hypothesise that individuals with asthma have an increased risk of community-acquired *E coli* BSI, as compared to those without asthma. To test this hypothesis, we conducted a population-based retrospective case--control study.

Methods {#s2}
=======

This study was designed as a population-based case--control study.

Study population and setting {#s2a}
----------------------------

Olmsted County, Minnesota is an excellent setting to conduct a population-based epidemiological study such as this because medical care is virtually self-contained within the community (nearly all Olmsted County residents receive medical care from two medical centres in the community). The population characteristics of Olmsted County residents are similar to those of non-Hispanic white.[@R21] If one grants the authorisation for using medical record for research (almost 95% of Olmsted County residents), each patient is assigned a unique identifier under the auspices of the Rochester Epidemiology Project (REP).[@R22] Using REP resources, we previously demonstrated that incidence rates of asthma for this community are similar to other communities. The annual incidence rate of asthma in Rochester was 238 cases/100 000 persons, which is comparable to those in other communities such as Tecumseh, Michigan (250/100 000).[@R23]

Study participants: case ascertainment {#s2b}
--------------------------------------

To test our study hypothesis, we utilised a population-based incidence parent study, which previously identified the community-acquired cases to study antimicrobial resistance trends of *E coli* BSI in the community. Details of the case ascertainment have been described previously.[@R19] Briefly, using the microbiology databases at Mayo Clinic Rochester and Olmsted Medical Center, all eligible children and adults with monomicrobial *E coli* BSI (n=274) among Olmsted County residents from 1 January 1998 to 31 December 2007 (ie, a population-based all incident cases of *E coli* BSI) were identified based on the criteria suggested by Friedman *et al.*[@R24] As *E coli* BSI is required for inpatient parental treatment, community-acquired *E coli* BSI was defined by the isolation of *E coli* from blood cultures at the time of hospital admission or within 48 h after hospital admission for patients who did not fit the criteria for healthcare-associated infection according to the Friedman\'s criteria.[@R24] Medical records of all participants were reviewed by investigators of the previous study (MNA-H) to confirm the diagnosis of community-acquired *E coli* BSI, assess clinical features and determine the eligibility. Only community-acquired *E coli* BSI was included because nosocomial and healthcare-associated *E coli* BSI are unsuitable to address the aim of the present study (clinically, they are a high-risk population for *E coli* BSI and not representative of the study population). The index date of BSI was defined as the date when blood cultures that eventually grew *E coli* were obtained. Exclusion criteria for cases (and controls) included: (1) polymicrobial BSI caused by more than one microorganism, (2) blood cultures acquired at autopsy, (3) nosocomial and healthcare-associated *E coli* BSI, (4) non-Olmsted County residency at the time of index date of BSI, (5) no research authorisation for using medical record for research and (6) health conditions making ascertainment of asthma difficult listed in [box 1](#bx1){ref-type="boxed-text"}.

###### Definition of asthma

Patients were considered to have *definite* asthma if a physician had made a diagnosis of asthma with the first two conditions and/or if each of the following three conditions were present, and they were considered to have *probable* asthma if only the first two conditions were present: History of cough with wheezing, and/or dyspnoea, or history of cough and/or dyspnoea plus wheezing on examinationSubstantial variability in symptoms from time to time or periods of weeks or more when symptoms were absent, andTwo or more of the following: Sleep disturbance by nocturnal cough and wheezeNon-smoker (14 years or older)Nasal polypsBlood eosinophilia higher than 300/μLPositive wheal and flare skin tests or elevated serum IgEHistory of hay fever or infantile eczema or cough, dyspnoea and wheezing regularly on exposure to an antigenPulmonary function tests showing one FEV~1~ or FVC less than 70% predicted and another with at least 20% improvement to an FEV~1~ of higher70% predicted or methacholine challenge test showing 20% or greater decrease in FEV~1~Favorable clinical response to bronchodilator (eg, documented improvement of respiratory symptoms or FEV~1~ in spirometry after bronchodilator therapy)

Patients were excluded from the study if any of these conditions were present: Tracheobronchial foreign body at or about the incidence dateHypogammaglobulinaemia (IgG less than 2.0 mg/mL) or other immunodeficiency disorderWheezing occurring only in response to anaesthesia or medicationsBullous emphysema or pulmonary fibrosis on chest radiographPiZZ α~1~-antitrypsinCystic fibrosisOther major chest disease such as juvenile kyphoscoliosis or bronchiectasis FVC forced vital capacity; FEV~1~, forced expiratory volume in 1 sPulmonary function tests that showed FEV~1~ to be consistently below 50% predicted or diminished diffusion capacity

Selection of control participants {#s2c}
---------------------------------

Control participants were randomly selected with 1:1 matching from Olmsted County residents who had not had a history of *E coli* BSI at the end of the study period. Briefly, a list of potential control participants who had received medical care from either Mayo Clinic or Olmsted Medical Center and who met the matching criteria was generated and randomly selected from the REP database for the present study. The matching criteria included: (1) gender, (2) birth date (within 6 months for those \<18 years of age and within 1 year for those \>18 years of age), (3) the same clinic registration year as matched case (within 1 year) and (4) closest clinic visit to index date of matched case within 1 year. The index date for control participants was defined as the closest (within 1 year) clinic visit date to index date of BSI for their corresponding matched case. Based on the number of cases and controls enroled in this present study (259 pair), assuming 8% of asthma prevalence among controls, this present study had 80% power to detect an effect size of 2.27 of OR (16.5% of asthma in cases). This effect size was smaller than the reported effect sizes for the association between asthma and risk of microbial infection (OR 2.4--6.7) suggesting adequate statistical power to address the study aim.[@R6] [@R10]

Exposure ascertainment (asthma status) {#s2d}
--------------------------------------

For determining asthma status of all cases and controls, we conducted comprehensive medical record reviews to apply predetermined criteria for asthma as performed in our previous work.[@R5] [@R6] The criteria are delineated in [box 1](#bx1){ref-type="boxed-text"}. These criteria have been extensively used in research for asthma epidemiology and were found to have high reliability.[@R25; @R26; @R27; @R28; @R29; @R30] We included definite as well as probable asthma according to the criteria prior to the index date of BSI cases because most probable asthmatics become definite over time.[@R6] [@R31] The incidence dates (the first date when one met the criteria for asthma) for all patients with asthma were determined; thus, we were able to discern the temporal relationship between asthma status (exposure) and *E coli* BSI (outcome). The risk of *E coli* BSI was assessed in relation to the current asthma status[@R32]: remission (no asthma symptoms, no asthma-related visits or no asthma medications for at least 3 years prior to index date); active or current asthma (presence of clinical symptoms, asthma-related visits or asthma medications within 1 year prior to index date) and inactive (not current) asthma (presence of asthma symptoms, asthma-related visits or asthma medications within 1--3 years prior to index date).

Other variables {#s2e}
---------------

Pertinent covariates and confounders were collected from medical records: sociodemographic variables (age, gender, ethnicity and educational status), asthma medications including inhaled and systemic corticosteroids, family history of asthma, atopic status based on sensitisation against aeroallergens and food allergens, smoking status (either active or passive exposure to tobacco smoke), vaccination status and comorbid conditions at the time of index date as listed in [table 1](#BMJOPEN2013003857TB1){ref-type="table"}. The period of data collection was from 1 October 2011 to 30 May 2012.

###### 

Sociodemographic and clinical characteristics of patients with *Escherichia coli* blood stream infection and their matched control participants

  Characteristics                                    Case (n=259)   Control (n=259)   Unadjusted OR\* (95% CI)   p Value
  -------------------------------------------------- -------------- ----------------- -------------------------- ---------
  Age (years)                                        61±22          61±22             1.14 (0.78 to 1.67)        0.497
  Female gender                                      179 (69%)      179 (69%)         --                         
  Ethnicity                                                                                                      \<0.001
   Caucasian (non-Hispanic)                          222 (86%)      245 (95%)         Referent                   
   Other                                             37 (14%)       14 (5%)           4.83 (2.01 to 11.64)       
  Education status                                                                                               0.004
   Some high school or less                          45 (17%)       21 (8%)           Referent                   
   High school graduate                              95 (37%)       87 (34%)          0.50 (0.27 to 0.93)        
   Some college or more                              110 (42%)      143 (55%)         0.33 (0.18 to 0.62)        
   Unknown                                           9 (3%)         8 (3%)            --                         
  Influenza vaccination 1 year prior to index date   95 (37%)       110 (42%)         0.75 (0.51 to 1.10)        0.145
  PPV23 prior to index date                          117 (45%)      114 (44%)         1.08 (0.69 to 1.68)        0.736
  Food allergy                                       16 (6%)        6 (2%)            2.67 (1.04 to 6.81)        0.040
  Asthma                                             37 (14%)       16 (6%)           2.75 (1.42 to 5.32)        0.003
  High-risk conditions                                                                                           
   Alcohol addiction                                 17 (7%)        1 (0%)            17.00 (2.26 to 127.75)     0.006
   Autoimmune disease‡                               9 (3%)         3 (1%)            3.00 (0.81 to 11.08)       0.099
   Chronic obstructive lung disease                  12 (5%)        9 (3%)            1.37 (0.55 to 3.42)        0.493
   Chronic renal insufficiency                       30 (12%)       4 (2%)            9.67 (2.94 to 31.73)       \<0.001
   Congestive heart failure                          19 (7%)        2 (1%)            18.00 (2.40 to 134.84)     0.005
   Coronary artery disease                           52 (20%)       40 (15%)          1.46 (0.89 to 2.41)        0.136
   Dementia                                          16 (6%)        7 (3%)            3.25 (1.06 to 9.97)        0.039
   Diabetes mellitus                                 50 (19%)       24 (9%)           2.53 (1.44 to 4.43)        0.001
   History of stroke                                 15 (6%)        10 (4%)           1.71 (0.67 to 4.35)        0.257
   Immobilisation§                                   10 (4%)        1 (0%)            10.00 (1.28 to 78.12)      0.028
   Immunosuppressive therapy                         25 (10%)       4 (2%)            8.00 (2.41 to 26.57)       0.001
   Malignancy                                        21 (8%)        12 (5%)           2.00 (0.90 to 4.45)        0.090
   Recurrent urinary tract infection                 29 (11%)       2 (1%)            14.50 (3.46 to 60.77)      \<0.001
   Transplant recipients                             8 (3%)         0 (0%)            --                         
   Urinary incontinence                              46 (18%)       20 (8%)           2.86 (1.55 to 5.25)        0.001
  Other condition¶                                   14 (5%)        0 (0%)            --                         --
  Smoke                                                                                                          0.058
   No (including ex-smoker)                          206 (80%)      222 (86%)         Referent                   
   Active                                            53 (20%)       37 (14%)          1.59 (0.98 to 2.58)        

\*OR based on matched analysis taking into account gender, birthday, residency and follow-up duration

†Comorbidity conditions are not mutually exclusive.

‡Autoimmune disease includes systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and other autoimmune diseases.

§Immobilisation includes hemi/para/quadri-plegia.

¶Other conditions include use of urinary catheter, device, genitourinary procedures (eg, prostate biopsy), and congenital anomaly.

PPV23, 23-valent pneumococcal polysaccharide vaccine.

Statistical analysis {#s2f}
--------------------

Formal comparison of asthma and other suspected risk factors between matched cases and controls was performed using conditional logistic regression, with community-acquired *E coli* BSI as the target of prediction. All factors were analysed for a univariate association with BSI and any variables meeting the Greenland entry criteria (p\<0.2) were carried forward into a final multivariable model.[@R33] ORs from univariate (unadjusted) and multivariable (adjusted) models are reported to express the magnitude of association in terms of the likelihood of being a case. We calculated the population attributable risk percentage (PAR%) of asthma for community-acquired *E coli* BSI using the formula established by Miettinen.[@R34] Statistical significance was tested at a two-sided α error of 0.05. All analyses were carried out with the statistical software package SAS, V.9.2 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Study subjects {#s3a}
--------------

Of the 274 patients who were identified in the original study, 259 were eligible for the present study. Fifteen patients were excluded: five for consistent FEV~1~ \<50%, two for restrictive lung disease, two for significant kyphoscoliosis, two for bronchiectasis, one for cystic fibrosis, one for pulmonary fibrosis and two due to non-Olmsted County residency. Of the eligible 259 cases, 179 (69%) were women, 249 (96%) were 18 years of age or older (age mean±SD, 61±22 years) and 222 (86%) were Caucasian. The characteristics of the cases and their matched controls, and the individual associations with community-acquired *E coli* BSI, are summarised in [table 1](#BMJOPEN2013003857TB1){ref-type="table"}. There were only 10 asthmatics on moderate-dose or high-dose inhaled corticosteroid (ICS) and two asthmatics on systemic corticosteroid at the time of the index date. Comparing participants with asthma versus those without, there was no significant difference in the proportions, who had received influenza vaccine (40% vs 40%, p=0.99) or 23-valent pneumococcal polysaccharide vaccine (PPV23; 49% vs 44%, p=0.49) within 1 year prior to index date.

Association between asthma and risk of community-acquired *E coli* BSI {#s3b}
----------------------------------------------------------------------

Of the 259 cases, 37 (14%) had a history of asthma prior to the index date of community-acquired *E coli* BSI, compared with 16 of 259 (6%) controls (unadjusted OR 2.75; 95% CI 1.42 to 5.32; p=0.003). Of the 37 case participants with asthma, 33 (89%) had definite asthma and 4 (11%) had probable asthma. Of the 16 controls with asthma, 12 (75%) had definite asthma and 4 (25%) had probable asthma. Among all 53 asthmatics, 18 were on ICS therapy at the index date (8 on low-dose ICS and 10 on moderate to high-dose ICS therapy). The effect of asthma on risk of community-acquired *E coli* BSI, independent of other risk factors, is summarised in [table 2](#BMJOPEN2013003857TB2){ref-type="table"}. Participants with a history of asthma by predetermined criteria for asthma in [box 1](#bx1){ref-type="boxed-text"} had a nearly threefold higher risk of developing community-acquired *E coli* BSI compared to those without asthma, controlling for all potential confounding factors (adjusted OR 2.74; 95% CI 1.11 to 6.76; p=0.029). The PAR% of asthma by predetermined criteria for asthma in [box 1](#bx1){ref-type="boxed-text"} for the risk of *E coli* BSI was 9%. The p values for testing a significant interaction between asthma and categorised age were as follows: p=0.285 for age cut-off of 65 years (ie, ≥65 vs \<65 years), p=0.958 for age cut-off of 40 years (ie, ≥40 vs \<40 years) and p=0.417 for age cut-offs of 40 years and 65 years (ie, \<40, 40--65, vs \>65 years). As a result, we have no evidence of a differential asthma effect across age strata. Additional characteristics of asthma were also evaluated for an association with risk of community-acquired *E coli* BSI (see [table 3](#BMJOPEN2013003857TB3){ref-type="table"}). Adjusted for other factors, active asthma was associated with increased risk of *E coli* BSI but for asthmatics on ICS therapy compared to non-asthmatics; however, the overall three-level effect was not statistically significant (p=0.079).

###### 

A multivariable conditional logistic regression model for the association between asthma and risk of community-acquired *Escherichia coli* bloodstream infection

  Characteristics                                    Case (n=259)   Control (n=259)   Adjusted OR\* (95% CI)   p Value
  -------------------------------------------------- -------------- ----------------- ------------------------ ---------
  Ethnicity                                                                                                    0.003
   Caucasian (non-Hispanic)                          222 (86%)      245 (95%)         Referent                 
   Other                                             37 (14%)       14 (5%)           5.90 (1.85 to 18.84)     
  Education status                                                                                             0.646
   Some high school or less                          45 (17%)       21 (8%)           Referent                 
   High school graduate                              95 (37%)       87 (34%)          0.89 (0.37 to 2.14)      
   Some college or more                              110 (42%)      143 (55%)         0.65 (0.28 to 1.50)      
   Unknown                                           9 (3%)         8 (3%)            --                       
  Influenza vaccination 1 year prior to index date   95 (37%)       110 (42%)         0.58 (0.33 to 1.02)      0.058
  Food allergy                                       16 (6%)        6 (2%)            3.51 (0.94 to 13.11)     0.062
  Asthma                                             37 (14%)       16 (6%)           2.74 (1.11 to 6.76)      0.029
  Active smoking                                     53 (20%)       37 (14%)          1.31 (0.69 to 2.47)      0.412
  High-risk conditions                                                                                         
   Alcohol addiction                                 17 (7%)        1 (0%)            32.31 (1.91 to 546.18)   0.016
   Autoimmune diseases                               9 (3%)         3 (1%)            1.79 (0.23 to 13.72)     0.574
   Chronic renal insufficiency                       30 (12%)       4 (2%)            4.76 (1.16 to 19.59)     0.030
   Congestive heart failure                          19 (7%)        2 (1%)            9.86 (0.93 to 104.59)    0.058
   Coronary artery disease                           52 (20%)       40 (15%)          0.81 (0.37 to 1.77)      0.593
   Dementia                                          16 (6%)        7 (3%)            4.14 (0.96 to 17.96)     0.057
   Diabetes mellitus                                 50 (19%)       24 (9%)           2.39 (0.97 to 5.87)      0.057
   Immobilisation                                    10 (4%)        1 (0%)            39.86 (2.30 to 690.42)   0.011
   Immunosuppressive therapy                         25 (10%)       4 (2%)            8.51 (1.32 to 54.96)     0.024
   Malignancy                                        21 (8%)        12 (5%)           2.18 (0.59 to 8.11)      0.243
   Recurrent urinary tract infection                 29 (11%)       2 (1%)            13.54 (2.42 to 75.65)    0.003
   Urinary incontinence                              46 (18%)       20 (8%)           2.57 (1.05 to 6.26)      0.038

\*Adjusted variables included all variables included in this table.

###### 

Association of asthma control status and therapy with risk of community-acquired *Escherichia coli* bloodstream infection

  Asthma characteristics                 Total (n=518)   Unadjusted OR (95% CI), p Value   Adjusted OR\* (95% CI), p Value
  -------------------------------------- --------------- --------------------------------- ---------------------------------
  Inhaled corticosteroid therapy (ICS)                   p=0.009†                          p=0.079†
   No asthma                             465 (90%)       Referent                          Referent
   Asthma without ICS                    35 (7%)         1.90 (0.88 to 4.09)               1.99 (0.67 to 5.94)
   Asthma with ICS                       18 (3%)         7.00 (1.59 to 30.80)              5.33 (0.90 to 31.66)
  Asthma status‡                                         p=0.005†                          p=0.067†
   No asthma                             465 (90%)       Referent                          Referent
   Remission or inactive asthma          17 (3%)         1.25 (0.45 to 3.50)               1.25 (0.25 to 6.30)
   Active or current asthma              36 (7%)         4.37 (1.80 to 10.62)              3.89 (1.23 to 12.28)

\*Adjusted variables included all factors reported in the multivariable model (see [table 2](#BMJOPEN2013003857TB2){ref-type="table"}) except for dichotomous asthma status.

†p Value for overall comparison.

‡Active or current asthma was defined as the presence of asthma-related events including asthma symptoms, or use of asthma medications, and outpatient/emergency department/hospitalisation for asthma within 1 year prior to index date of *E coli* BSI; remission of asthma was defined as the absence of asthma-related events \>3 years prior to index date; inactive (not current) asthma was defined as the presence of asthma-related events within 1--3 years prior to index date.

Other variables and *E coli* BSI {#s3c}
--------------------------------

Several of the high-risk conditions, as well as non-Caucasian ethnicity, were independently associated with increased risk of community-acquired *E coli* BSI (see [tables 1](#BMJOPEN2013003857TB1){ref-type="table"} and [2](#BMJOPEN2013003857TB2){ref-type="table"}). A history of food allergy was found in 16 (6%) of 259 cases as compared with 6 (2%) of 259 controls (adjusted OR 3.51; 95% CI 0.94 to 13.11; p=0.062). Neither allergic rhinitis (p=0.82) nor atopic dermatitis (p=0.87) was found to be significantly associated with community-acquired *E coli* BSI.

Discussion {#s4}
==========

To our knowledge, this is the first population-based, case-control study that demonstrated an association between asthma and risk of non-respiratory bacterial infection such as community-acquired *E coli* BSI. This association was independent of other risk factors including age, gender, follow-up duration, ethnicity, educational level and comorbid conditions (adjusted OR 2.74; 95% CI 1.11 to6.76; p=0.029). Analyses by different age cut-offs showed that the results were not affected by age (eg, younger vs older than 40 years of age). Given either the previously reported non-association (HR 1.29, 95% CI 0.53 to 3.12) or a protective effect (HR 0.52, 95% CI 0.36 to 0.76) of ICS therapy on risk of pneumonia in asthmatics[@R35] and a small number of asthmatics with moderate or high-dose ICS in our study (10 of 53, 19%), we suspect that active or current asthma (or collectively those given ICS therapy) might be related to risk of community-acquired *E coli* BSI instead of ICS alone. There were only two patients with asthma on systemic corticosteroid therapy at the time of the index date; therefore, exposure to systemic corticosteroid therapy was unlikely to account for the observed association. We believe that susceptibility bias (eg, covariate imbalance at baseline) is unlikely to account for the association found in our study given the full adjustment for potential confounders. One concern could be detection bias stemming from a situation where exposure status (asthma status) systematically affects detection of outcomes. However, given that *E coli* BSI is a life-threatening condition, this is unlikely and also there was no significant difference in symptom duration from BSI-related symptom to index date between asthma and non-asthma in cases (4.7±5.5 vs 5.2±5.5 days, p=0.61). Since detection of asthma depends on follow-up duration from registration to index date of community-acquired *E coli* BSI, we designed our study to ensure that duration was similar between cases and controls. Asthma prevalence in controls in our study was 6%, which is similar to that in adults (7%) in the USA (5.5% for men and 9.7% for women).[@R36] Also, the prevalence of other common chronic conditions such as coronary heart disease in our study (15%) was similar to the national average (7.1% for adults aged 45--64 years and 19.8% for adults aged ≥65 years) suggesting that our control group may reasonably represent a general population of adults in the USA.[@R3] There were no significant differences in influenza and PPV23 vaccination rates between cases and controls, which may imply similar access to healthcare services. Also, food allergy approached a statistically significant association with the risk of *E coli* BSI but other atopic conditions did not. This is probably due to greater misclassification bias of ascertainment of allergic rhinitis and atopic dermatitis by International Classification of Diseases (ICD)-9 code compared to asthma status and food allergy by predetermined criteria in our study. Taken together, our study results suggest that asthma status is independently associated with risk of community-acquired *E coli* BSI.

There are only a few previous studies, which assessed the incidence of *E coli* BSI and risk factors associated with its development, including asthma. One study showed a higher risk of community-acquired *E coli* BSI in asthmatics compared to non-asthmatics among those over 65 years of age (5.5% vs 1%).[@R37] However, another study showed reduced risk of *E coli* BSI in asthmatics (rate ratio: 0.3; 95% CI 0.2 to 0.4) compared to that in the total regional population.[@R38] These studies have significant limitations including no a priori hypothesis testing on the relationship between asthma and risk of community-acquired *E coli* BSI, utilisation of administrative data from healthcare organisations or case reports, ascertainment of *E coli* BSI cases and asthma based on ICD-9 code, inclusion of only elderly patients aged over 65 years[@R37] and no concurrent control group.[@R38] Thus, our study is the first population-based case--control study that demonstrated a relationship between asthma and risk of community-acquired *E coli* BSI. Several studies showed increased risks of microbial infections in asthmatics,[@R5; @R6; @R7] [@R10] [@R11] but these studies only addressed the relationship between asthma and airway infections.

The mechanisms underlying the apparent association between asthma and risk of community-acquired *E coli* BSI are unknown. Whether previously reported impaired innate immune factors that may predispose to infections due to viruses[@R13] [@R39] [@R40] and other bacteria are operative in community-acquired *E coli* BSI is undefined. Recently, Habibzay *et al*[@R11] reported impaired innate immunity against pneumococci through impaired TLR-receptor signal transduction by house dust mite allergic sensitisation resulting in reduced neutrophil recruitment and increased risk of pneumococcal infection in the airways. It is worth investigating whether allergic sensitisation can induce similar impairment of innate immunity through TLR-4 for Gram-negative bacteria in genitourinary or gastrointestinal tracts in asthmatics. Also, an adaptive immune response to Gram-negative bacteria might be altered in asthmatics,[@R41] which may affect susceptibility to Gram-negative bacterial infection. For example, Koch *et al* reported impaired type 1 helper T cell (Th1) response (interleukin-12-induced interferon-γ release from T lymphocytes) to endotoxin from *Salmonella enteritidis* in asthmatics.[@R42] Further studies are needed to address our study findings.

The main strengths of our study are a population-based study design and include the epidemiological merits of self-contained healthcare environment with comprehensive medical record system for research. We identified population-based all incident community-acquired *E coli* BSI cases based on the Friedman criteria. We ascertained asthma status by applying predetermined criteria independent of a physician diagnosis of asthma or ICD-9 code. Also, our study has inherent limitations as a retrospective study. We could not obtain detailed information on certain variables such as atopic sensitisation data or smoking history (eg, duration or the number of cigarettes a day) but we assumed these data to be missing at random (ie, it is subject to non-differential misclassification bias for comparison groups of interest). Although our criteria for asthma was based on medical record review, given the absence of a gold standard for asthma, the retrospective investigation for feasibility (due to infrequent *E coli* BSI) and the extensive use of the criterion in previous asthma research, we believe the criterion is unlikely to result in a significant bias affecting interpretation of the results. Our study finding that asthma prevalence among controls was similar to that at the national level should mitigate this concern. Our study participants were predominantly white which might limit generalisability of our results to other ethnic groups. Our study participants were relatively an older population affected by many comorbid conditions, which might confound the study results. Therefore, we adjusted the association between asthma and risk of *E coli* BSI for each comorbid condition individually in our multivariate model. Since the prevalence of comorbid conditions is related to age, we examined the effect of the interaction between age and asthma. We found that the main results on the association between asthma and risk of *E coli* BSI did not appear to be significantly affected by various cut-offs of age suggesting the results did not differ by age group (younger vs older group).

In conclusion, asthmatics might be at an increased risk of non-respiratory tract bacterial infections, including community-acquired *E coli* BSI. The mechanisms responsible for this association are yet to be defined while additional investigations replicate our study findings.
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